KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) EBITDA Margin (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed EBITDA Margin for 10 consecutive years, with 15136.34% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 1500736.0% to 15136.34% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 16484.84% through Dec 2025, down 1550311.0% year-over-year, with the annual reading at 16484.84% for FY2025, 1550311.0% down from the prior year.
  • EBITDA Margin hit 15136.34% in Q4 2025 for CRISPR Therapeutics AG, down from 11866.82% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 84.27% in Q2 2021 to a low of 1732650.0% in Q4 2022.
  • Historically, EBITDA Margin has averaged 117090.62% across 5 years, with a median of 15448.3% in 2021.
  • Biggest five-year swings in EBITDA Margin: plummeted -173152166bps in 2022 and later soared 173269873bps in 2023.
  • Year by year, EBITDA Margin stood at 1128.34% in 2021, then crashed by -153457bps to 1732650.0% in 2022, then skyrocketed by 100bps to 48.73% in 2023, then crashed by -365bps to 128.98% in 2024, then crashed by -11635bps to 15136.34% in 2025.
  • Business Quant data shows EBITDA Margin for CRSP at 15136.34% in Q4 2025, 11866.82% in Q3 2025, and 23390.47% in Q2 2025.